مباشر
FierceBiotechAstraZeneca plucks preclinical EGFR degrader from Pinetree for $25MNovo NordiskIs Novo Nordisk's GLP-1 dominance fading after Lilly's clinical wins? - MSNSiemens HealthineersSiemens Healthineers: A €6 Billion Diagnostics Exit and a Coming Spin-Off as Shares Hit Rock Botto - AD HOC NEWSBioPharma DiveAvalyn, in pursuit of better lung drugs, banks $300M in an IPOInsilico MedicineInsilico Medicine Secures IND Clearance For Rentosertib Inhalation Solution To Advance Targeted IPF Therapy - BioPharma APACMedtronicMedtronic Advances First Clinical Cases with Stealth AXiS™ Surgical System, Demonstrating the Power of Connected Smart Ecosystems Across Neurosurgery - Orthopedics This WeekBoston ScientificBoston Scientific Corporation (BSX): Stephen Mandel Opens New Position in Medical Device Firm - Yahoo Finance10x Genomics NewsVanguard holds 6.17M shares of 10X Genomics (NASDAQ: TXG), 5.24% stake - Stock Titan10x Genomics Blog10x Genomics investors can watch management at a May 13 BofA chat - Stock Titan10x Genomics News10x Genomics to Participate in the BofA Securities 2026 Healthcare Conference - PR Newswire10x Genomics Blog10x Genomics to Participate in the BofA Securities 2026 Healthcare Conference - Yahoo Finance UKFierceBiotechFDA hits Newron’s phase 3 schizophrenia trial with clinical hold in US after patient death
Merck KGaA ٢٧ أبريل ٢٠٢٦

Merck KGaA: Small Breakout In 2026, Followed By Normalization (OTCMKTS:MKGAF) - Seeking Alpha

Merck KGaA: Small Breakout In 2026, Followed By Normalization (OTCMKTS:MKGAF) - Seeking Alpha

المصدر
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.